Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate

Related Keywords

United States , Texas , China , Ireland , Dublin , Vancouver , British Columbia , Canada , American , Zymework Azymetric , Diana Papove , Jack Spinks , Andrean Flynn , Rob Iannone , Kristin Bhavnani , University Of Texas Md Anderson Cancer Center , Prnewswire Jazz Pharmaceuticals , Nasdaq , Zymeworks Inc , Exchange Commission , European Medicines Agency , American Society Of Clinical Oncology , Corporate Communications , Securities Exchange , Department Of Investigational Cancer Therapeutics , Beigene Ltd , Jazz Pharmaceuticals Ireland Limited , Department Of Gastrointestinal Medical Oncology , Commission File No , Jazz Pharmaceuticals , Drug Administration , Lancet Oncology , American Society , Clinical Oncology , Annual Meeting , Kaplan Meier , Shubham Pant , Gastrointestinal Medical Oncology , Investigational Cancer Therapeutics , Objective Response Rate , Control Rate , Response Greater , Abstract Number , Breakthrough Therapy , Fast Track , Orphan Drug , Drug Evaluation , Caution Concerning Forward Looking , Jazz Pharmaceutical , Commission File , Jazz Pharmaceutical Annual Report , Quarterly Report , Securities Act , Securities Exchange Act , Media Contact , Strategic Brand , Investor Contact , Investor Relations , Injury Incidence , Global Burden , Disease Study , Cancer Metastasis , Jazz , Pharmaceuticals , Zymeworks , Present , Positive , Pivotal , Hase , Trial , Data , Disco , 023 , Valuating , Zanidatamab , Ther2 , Simplified , Miliary , Tract , Cancers ,